The mean psychometric values before and six weeks after limbic leucotomy N= 35. Four patients were unable to complete the forms because of language difficulties and one patient was too disturbed (Kelly 1972) . The target site may be moved a few millimetres if no physiological changes are obtained. This procedure is used to increase the accuracy of lesion placement. Lesions are made in the lower medial quadrant to disconnect some frontolimbic pathways, and in the cingulate gyrus to interrupt one of the important limbic circuits of Papez .
The results of stereotactic limbic leucotomy have been assessed psychologically and physiologically at six weeks (Kelly, Richardson, Mitchell-Heggs, Greenup, Chen & Hafner 1973) .
The patients, who were mainly suffering from obsessional neurosis, depression and anxiety, had a mean duration of symptoms of eleven years, with a mean number of hospital admissions of 4.5. Thirty-six of the 40 patients had been treated previously with ECT, 27 had received psychotherapy and 24 modified narcosis; 11 had made a determined suicidal attempt.
Postoperative assessment showed a significant reduction in anxiety (Taylor, Hamilton, MHQ), depression (Beck, Hamilton, MHQ) neuroticism (Maudsley Personality Inventory) and obsessions (MHQ) ( Table 1 ). The postoperative IQ assessment showed a significant increase in the mean full-scale and performance IQ on the Wechsler Adult Intelligence Scale. This was probably due to a practice effect, but on none of the subscales of the WAIS was there a significant decrease in postoperative score. The patients are being reevaluated psychologically and physiologically at one year, and are being seen by an independent psychiatrist before and one year after operation.
During the past ten years a greater understanding of the nature of pathological anxiety has been achieved, and several new types of treatment are now available for its alleviation. The work of assessing these will be a slow but worth-while endeavour.
Dr David Wheatley (Twickenham, Middlesex)
The benzodiazepines are the mainstay of treatment of the milder forms of anxiety in general practice; this may be because of the safety factor, since they are free of the danger of death by overdose. Nevertheless, I believe that the benzodiazepines are specifically better than the barbiturates, as was demonstrated in a trial undertaken by the General Practitioner Research Group. Chlordiazepoxide was compared to amylobarbitone over eight weeks, with cross-over of medications at four weeks; 134 patients were treated. The trial was double blind, with random allocation of cases; 70 received chlordiazepoxide first and 64 amylobarbitone first. Irrespective of the order, better results were recorded with chlordiazepoxide, and on the combined figures the final difference was statistically significant at the 1 % level.
Sedation is also important in neurotic depression and our group has compared phenobarbitone, a purely sedative drug, to the antidepressant imipramine, in chronic cases, in similar manner. The trial involved 170 patients, 88 receiving imipramine first and 82 phenobarbitone first. Summating the results for both series, there were no significant differences, except at two weeks, when there was greater improvement with phenobarbitone (P <0.05). Allaying anxiety symptoms in the milder forms of depression is important and this may be more rapidly achieved with antianxiety drugs than with specific antidepressants.
In our study on propranolol, to which Dr Bonn referred, we compared this ,B-adrenergic blocking drug to chlordiazepoxide, in 105 patients suffering from anxiety. Patients were treated in a random order, on the double-blind basis, with one or other drug for six weeks. In fact, 51 received propranolol and 54 chlordiazepoxide, and there were no overall differences in the anti-anxiety effects of the two drugs. However, in depression and sleep disturbance, chlordiazepoxide produced better results (P<0.05). The importance of work in this field is that it represents the development of a new idea; for we have been guilty of complacency, engendered though it has been by the pharmaceutical companies, in the belief that chemical manipulation of established formula will eventually produce variants with startling new actions.
Finally, I would refer to another study undertaken by our group, relating the response to treatment with chlordiazepoxide to the doctors' and patients' attitudes towards the outcome of treatment. There was, in fact, a very marked relationship, with significant differences at the 1 % level between optimistic, indifferent and pessimistic attitudes, for both doctors and patients. However, in a similar study of imipramine in depression no such differences were revealed.
Therefore, when we are considering progress in anxiety, it may be as well to remember that one of the most potent factors in treatment is that provided by the doctor's encouragement to the patient.
